Table 3.

Intergroup comparison of SF-36 somatic and mental scores at baseline and at 3, 6 and 12 months of women on 24/4 regimen 17β-estradiol (1.5 mg) and Nomegestrol Acetate (2.5 mg) (E2/NOMAC) combined oral contraceptive, or on Dienogest (DNG) 2 mg daily

SF-36 somatic score	Baseline	3rd month follow-up	6th month follow-up	12th month follow-up
A
E2/NOMAC Group	60 ± 10	68 ± 10	75 ± 8	80 ± 11
DNG Group	57 ± 18	70 ± 7	80 ± 19	84 ± 9
p	0.18 95% CI − 1.08 to 7.08	0.1 95% CI − 4.42 to − 0.42	0.01 95% CI − 9.08 to − 0.91	0.006 95% CI − 6.82 to − 1.17

SF-36 mental score	Baseline	3rd month follow-up	6th month follow-up	12th month follow-up
B
E2/NOMAC Group	60 ± 7	76 ± 8	84 ± 8	88 ± 9
DNG Group	62 ± 12	75 ± 9	86 ± 9	90 ± 10
p	0.16 95% CI − 4.75 to 0.75	0.4 95% CI − 1.39 to 3.39	0.1 95% CI − 0.41 to 0.62	0.1 95% CI − 4.67 to − 0.67